What is PathologyWatch?
PathologyWatch operates as a pivotal provider of digital dermatopathology solutions, specifically engineered to streamline the operational complexities faced by modern dermatology practices. By offering a comprehensive suite of services—ranging from rapid test result delivery to sophisticated clinician education and digital display interfaces—the company effectively bridges the gap between laboratory diagnostics and patient-centric care. Their market position is defined by a commitment to enhancing clinical efficiency, fostering seamless collaboration among healthcare providers, and ultimately optimizing patient outcomes through high-fidelity digital infrastructure.
How much funding has PathologyWatch raised?
PathologyWatch has raised a total of $34.3M across 4 funding rounds:
Unspecified
$2.3M
Series A
$5M
Unspecified
$2M
Series B
$25M
Unspecified (2019): $2.3M, investors not publicly disclosed
Series A (2020): $5M led by Rock Creek Capital and SpringTide Investments
Unspecified (2020): $2M supported by BioVentures Inc, Lateral Capital, Sky Ventures Group, Neue Fund, and BeniVC
Series B (2021): $25M featuring Ceros Capital Markets, Rock Creek Capital, Spark Growth Ventures, and SpringTide
Key Investors in PathologyWatch
Ceros Capital Markets
A global investing platform specializing in fundraising for MedTech and Biotech companies, with a focus on disruptive technologies in medical devices and digital health.
Spark Growth Ventures
A community-driven venture capital firm based in San Diego that supports mid-stage technology startups through a vast network of industry experts and collaborative resources.
Lateral Capital
A mission-driven venture fund that partners with visionary entrepreneurs to build essential digital infrastructure, providing flexible and patient capital from seed to growth stages.
What's next for PathologyWatch?
With the successful completion of its latest financing round, PathologyWatch is poised to enter a critical phase of enterprise-level scaling. The strategic deployment of this capital will likely focus on expanding its digital footprint, enhancing its proprietary connectivity platform, and deepening its penetration into the global dermatology market. As the company transitions from its established growth phase into a more mature operational cycle, the focus will shift toward long-term value creation, potentially through the integration of advanced diagnostic analytics and the further refinement of its patient-facing support resources. This trajectory suggests a sustained commitment to disrupting traditional dermatopathology models through technological innovation and operational excellence.
See full PathologyWatch company page
